Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

ClinicalTrials.gov ID: NCT02942290

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02942290. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Study identification

NCT ID
NCT02942290
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
AbbVie
Industry
Enrollment
134 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 12, 2017 (Actual)
Primary completion
Apr 15, 2026 (Actual)
Completion
Apr 15, 2026 (Actual)
Last update posted
Aug 12, 2026

2017 – 2026

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155 Tucson Arizona 85719-1478 —
The University of Chicago Medical Center /ID# 153673 Chicago Illinois 60637-1443 —
University of Maryland, Baltimore /ID# 153669 Baltimore Maryland 21201 —
Tufts Medical Center /ID# 153672 Boston Massachusetts 02111-1552 —
Dana-Farber Cancer Institute /ID# 152735 Boston Massachusetts 02215 —
Washington University-School of Medicine /ID# 153671 St Louis Missouri 63110 —
Columbia University Medical Center /ID# 153661 New York New York 10032-3729 —
Weill Cornell Medical College /ID# 155524 New York New York 10065 —
Oregon Medical Research Center /ID# 152734 Portland Oregon 97239 —
University of Pittsburgh MC /ID# 153662 Pittsburgh Pennsylvania 15260 —
Tennessee Oncology-Nashville Centennial /ID# 222769 Nashville Tennessee 37203-1632 —
Vanderbilt University Medical Center /ID# 152738 Nashville Tennessee 37232-0011 —
UT MD Anderson Cancer Center /ID# 153809 Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02942290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2026 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.